 In this study, researchers compared the effectiveness and safety of anti-HCD treatments in patients with epilepsy and those without. They found that the effectiveness of anti-HCD treatment was high in both groups, regardless of their genotypes or stages of liver disease. Additionally, they concluded that the treatment was safe in patients with epilepsy. This article was authored by Monica Paskin-Simon, Jersey Jarosuex, Christoph Simon, and others.